883 related articles for article (PubMed ID: 36992275)
1. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
[TBL] [Abstract][Full Text] [Related]
2. The Race for Global Equitable Access to COVID-19 Vaccines.
Md Khairi LNH; Fahrni ML; Lazzarino AI
Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016194
[TBL] [Abstract][Full Text] [Related]
3. Sustainable vaccine manufacturing in low- and middle-Income countries.
Hayman B; Kumar Suri R; Downham M
Vaccine; 2022 Nov; 40(50):7288-7304. PubMed ID: 36334966
[TBL] [Abstract][Full Text] [Related]
4. Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future.
Pilkington V; Keestra SM; Hill A
Front Public Health; 2022; 10():821117. PubMed ID: 35321196
[TBL] [Abstract][Full Text] [Related]
5. Factors, enablers and challenges for COVID-19 vaccine development.
Excler JL; Saville M; Privor-Dumm L; Gilbert S; Hotez PJ; Thompson D; Abdool-Karim S; Kim JH
BMJ Glob Health; 2023 Jun; 8(6):. PubMed ID: 37277195
[TBL] [Abstract][Full Text] [Related]
6. Which roads lead to access? A global landscape of six COVID-19 vaccine innovation models.
Alonso Ruiz A; Bezruki A; Shinabargar E; Large K; Vieira M; Slovenski I; Liu Y; Agarwal S; Becker A; Moon S
Global Health; 2024 Mar; 20(1):25. PubMed ID: 38532484
[TBL] [Abstract][Full Text] [Related]
7. International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility.
Eccleston-Turner M; Upton H
Milbank Q; 2021 Jun; 99(2):426-449. PubMed ID: 33650737
[TBL] [Abstract][Full Text] [Related]
8. Strengthening the influenza vaccine virus selection and development process: Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014.
Ampofo WK; Azziz-Baumgartner E; Bashir U; Cox NJ; Fasce R; Giovanni M; Grohmann G; Huang S; Katz J; Mironenko A; Mokhtari-Azad T; Sasono PM; Rahman M; Sawanpanyalert P; Siqueira M; Waddell AL; Waiboci L; Wood J; Zhang W; Ziegler T;
Vaccine; 2015 Aug; 33(36):4368-82. PubMed ID: 26148877
[TBL] [Abstract][Full Text] [Related]
9. Risky business: COVAX and the financialization of global vaccine equity.
Stein F
Global Health; 2021 Sep; 17(1):112. PubMed ID: 34544439
[TBL] [Abstract][Full Text] [Related]
10. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
[TBL] [Abstract][Full Text] [Related]
11. Intellectual property licensing of therapeutics during the COVID-19 crisis: lessons learnt for pandemic preparedness and response.
Braimoh T; Burrone E; Gore C; Vijayaraghavan P
Global Health; 2024 Jul; 20(1):52. PubMed ID: 38956614
[TBL] [Abstract][Full Text] [Related]
12. Crisis-Critical Intellectual Property: Findings From the COVID-19 Pandemic.
Tietze F; Vimalnath P; Aristodemou L; Molloy J
IEEE Trans Eng Manag; 2022 Oct; 69(5):2039-2056. PubMed ID: 35938060
[TBL] [Abstract][Full Text] [Related]
13. Redressing COVID-19 vaccine inequity amidst booster doses: charting a bold path for global health solidarity, together.
Rackimuthu S; Narain K; Lal A; Nawaz FA; Mohanan P; Essar MY; Charles Ashworth H
Global Health; 2022 Feb; 18(1):23. PubMed ID: 35193616
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
16. More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap.
Borges LC; Zeferino de Menezes H; Crosbie E
Int J Health Policy Manag; 2022 Dec; 11(12):3101-3113. PubMed ID: 36028975
[TBL] [Abstract][Full Text] [Related]
17. Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General Meeting.
Kumar Suri R; Hayman B; Prasad SD; Makhoana M; Tippoo P
Vaccine; 2022 Jun; 40(26):3495-3505. PubMed ID: 35577632
[TBL] [Abstract][Full Text] [Related]
18. Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa.
Kana BD; Arbuthnot P; Botwe BK; Choonara YE; Hassan F; Louzir H; Matsoso P; Moore PL; Muhairwe A; Naidoo K; Ndomondo-Sigonda M; Madhi SA
Lancet Infect Dis; 2023 Aug; 23(8):e288-e300. PubMed ID: 37290473
[TBL] [Abstract][Full Text] [Related]
19. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.
So AD; Woo J
BMJ; 2020 Dec; 371():m4750. PubMed ID: 33323376
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
